CD274 and melanoma: Methods: 41 patients with previously untreated stage IV melanoma (known PD-L1 status by immunohistochemistry; 28–8 PharmDx) received ≥ 1 dose of BEMPEG (0.006 mg/kg) plus NIVO (360 mg) q3wks; 38 patients were efficacy-evaluable (≥ 1 post-baseline tumor scan).